Found: 9
Select item for more details and to access through your institution.
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
- Published in:
- Japanese Journal of Clinical Oncology, 2018, v. 48, n. 4, p. 367, doi. 10.1093/jjco/hyy016
- By:
- Publication type:
- Article
Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
- Published in:
- Japanese Journal of Clinical Oncology, 2017, v. 47, n. 7, p. 618, doi. 10.1093/jjco/hyx045
- By:
- Publication type:
- Article
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
- Published in:
- International Journal of Clinical Oncology, 2020, v. 25, n. 9, p. 1736, doi. 10.1007/s10147-020-01699-6
- By:
- Publication type:
- Article
Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma†.
- Published in:
- Japanese Journal of Clinical Oncology, 2012, v. 42, n. 9, p. 836, doi. 10.1093/jjco/hys110
- By:
- Publication type:
- Article
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 2, p. 251, doi. 10.1007/s12185-022-03481-y
- By:
- Publication type:
- Article
Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.
- Published in:
- Cancer Science, 2021, v. 112, n. 2, p. 725, doi. 10.1111/cas.14678
- By:
- Publication type:
- Article
Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9.
- Published in:
- Cancer Science, 2018, v. 109, n. 9, p. 2863, doi. 10.1111/cas.13721
- By:
- Publication type:
- Article
Phase I study of anti- CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non- Hodgkin lymphoma.
- Published in:
- Cancer Science, 2012, v. 103, n. 5, p. 933, doi. 10.1111/j.1349-7006.2012.02241.x
- By:
- Publication type:
- Article